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Effect of vasopressin antagonist on water excretion in inferior vcna cava
constriction. Elevated levets of plasma arginine vasopressin (AVP) have
been suggested to impair water excretion in congestive heart failure. In
the present study, to determine a role for AVP in the impaired water
excretion in rats with the inferior vena cava constriction (IVC), two
AVP antagonists were used in the JYC rats at the proximal portion of
the hepatic vein under the diaphragm and in sham—operated (control)
rats. After surgery, 48 hrs were allowed before the experiments were
started. A mean cardiac index of 260.0 12.3 mI/mm/kg in the IVC rats
was significantly lower than that in the control rats, 323.6 13.2
mi/mm/kg (P c 0.01). The rats were given an antidiuretic antagonist,
[1 -(-mercapto-j3, /3-cyclopentamethylenepropionic acid), 2-(O-ethyl)-
D-tyrosine, 4-valinel AVP (30 jig/kg) or the antagonist vehicle, i.p., and
20 mm later they were administered 30 mI/kg of water orally. Minimal
urinary osmolality (liosm) in the IVC rats receiving the vehicle was
significantly greater than the control rats (292.7 53.1 vs. 97.8 10.6
mOsm/kg H20, P < 0.01). The administration of the antidiuretie
antagonist in the IVC rats decreased minimal Uosm to 90.0 3.6
mosm/kg H20. This value was significantly lower than the vehicle rats
(P <0.01), and was a comparable level to minimal Uosm of 82.1 3.7
mOsm/kg H20 in the control rats receiving the antidiuretic antagonist.
The IVC rats excreted 51.4 5.9% of the water load in three hr, a value
significantly less than that excreted by the control rats, 95.1 6.0% (P
0.01). When treated with the antidiuretie antagonist, the percent of
water load excreted increased to 143.7 9.4% in the IVC rats. The
efficacy of the antidiuretie antagonist was associated with nonsnppres-
sible plasma AVP levels. The plasma AVP level of 2.1 0.6 pg/mI was
not sufficiently suppressed in the IVC rats by the administration of
water, which induced hypoosmolality. In contrast, in the control rats
plasma AVP was decreased to 0.7 0.2 pg/ml in the same situation.
However, the elevated AVP did not contribute to the maintenance of
blood pressure since the vasopressor antagonist, [1-(/3-mereapto-/3,
fl-cyclopentamethylenepropionic acid), 2-(O-methyl)-tyrosine] AVP,
did not affect mean arterial pressure. These results therefore indicate
that the non-osmotic release of AVP is inappropriately increased to
impair renal water excretion in the IVC rats and thc biological efficacy
of the antidiuretic antagonist in such a state is expected.
Clinical and laboratory experiments have demonstrated that
low output cardiac failure is associated with impaired water
excretion [1—3]. Persistent plasma levels of radioimmunoassay-
able arginine vasopressin (AVP) were shown in man and
animals hy other laboratories, in spite of levels of hypoosmolal-
ity which should suppress the osmotic release of AVP to
undetectable levels [4, 5]. Reversal of water retention by using
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a specific inhibitor of AVP would provide quantitative and
conclusive evidence for a role of AVP in water retention in a
model, which may stimulate some features of low output
cardiac failure. This is important since intrarenal factors may
also contribute to the impaired water excretion [6, 71. Such a
study is now possible because Manning and Sawyer have
developed novel antagonists of the antidiuretic effect of AVP
[8—121. We have already reported the reversal of the impaired
water excretion in glucocorticoid and mineraloeortieoid defi-
ciency with a specific and potent antagonist to the antidiuretic
effect of AVP [131.
In the present study, we determined whether AVP is impor-
tant in the pathogenesis of the impaired water excretion in rats
with the inferior vena eava constriction (IVC) by using the
antagonist to the antidiuretic effect of AVP. Also, whether or
not AVP contributes circulatory homeostasis in the IVC rats
was examined with the use of a specific antagonist to the
vascular effect of AVP.
Methods
Male Sprague—Dawley rats weighing 230 to 270 g were used in
the present experiments. Under ether anesthesia the abdomen
was opened via a midline incision. A portion of the abdominal
inferior vena cava between the take—off of the hepatic vein and
the diaphragm was carefully dissected out from the surrounding
tissues and then tied together with three pieces of polyethylene
(PE-lOO) tubing (Clay—Adams, Division of Beeton, Dickinson &
Co., Parsippany, New Jersey, USA) by silk thread. The poly-
ethylene tubes were then removed to produce the constriction
of the abdominal inferior vena cava (IVC). Sham—operated rats
were prepared in the same manner but without the constriction.
After surgery the animals were allowed free access to water and
food for 48 hrs and were subjected to the following experi-
ments.
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Systemic hemodynamic sludies
To determine changes in systemic hemodynamics of the IVC
rats, the two groups of animals were studied using a radioactive
mierosphere technique [14]. Briefly, after induction of anesthe-
sia with ether, polyethylene catheters (PE-50, Clay—Adams)
were inserted into the femoral artery and vein. A third catheter
of tapered PE-350 tubing (Clay—Adams) was advanced retro-
grade through the right carotid artery into the left ventricle for
mierospheres injection. Ventricular placement was confirmed
by the pressure—wave tracing at the time of catheterization and
50 Ishikawa er a!
by direct observation at the end of each experiment. The rats
were then placed in restraining cages (Shinnihon Sangyo Co.,
Tochigi, Japan), and allowed to awaken. At least two hrs passed
after the animals had awakened before the experiments were
started to determine cardiac output and renal blood flow by a
radioactive microsphere technique. The microspheres used
were 15.9 0.3 .t in diameter and were labelled with 5tCr
(specific activity, 11.42 mCi/g, New England Nuclear, Boston,
Massachusetts, USA). Mean arterial pressure (MAP) was mea-
sured. For each experiment, 0.6 ml of a 0.9% NaC1 solution
containing 1.4 x i05 microspheres was injected through the
carotid line in approximately five sec. Thereafter, the catheter
was flushed with 0.4 ml of 0.9% NaCl. The microspheres were
prepared as follows just before the injection. The radioactivity
of the solution containing 51Cr-microspheres was counted in a
Aloka Gamma Counter (Model ARC-600, Tokyo, Japan). The
solution was vigorously agitated using a vortex mixer for at
least five mm just prior to injection. Immediately prior to the
injection of the microspheres, the arterial blood collection was
started from the femoral artery line at a rate of 1 mi/mm for two
mm (Harvard pump, Harvard Apparatus Co., Dover, Massa-
chusetts). The animals were killed by an overdose of anesthetic.
Collected blood samples, the femoral artery line, the injection
syringes, and the carotid artery line were transferred into
separate plastic tubes to count the radioactivity. The heart and
the kidneys were also removed, weighed and counted for
radioactivity. Cardiac index, total peripheral vascular resist-
ance, renal blood flow and vascular resistance were calculated
as follows:
Injected microspheres (cpm)Cardiac index (mi/mm/kg) = X
Femoral blood (cpm)
Rate of collection of femoral arterial blood (mI/mm)
Body weight (kg)
Total peripheral vascular resistance
=
Mean arterial pressure (mm Hg)
(mm Hg/mI/mm/kg) Cardiac index (mI/mm/kg)
Rate of collection of femoral
arterial blood (mI/mm)
Kidney weight (g)
Renal vascular resistance
—
Mean arterial pressure (mm Hg)
(mm Hg/ml/min/g) Renal blood flow (ml/min/g)
Effect of inferior vena cava constriction on plasma AVP and
plasma osmolality
To determine the role of plasma AVP in water retention in
IVC rats, these experiments were performed in IVC rats and in
sham—operated rats. The animals were allowed free access to
water and food after operation. Forty-eight hrs later the animals
were decapitated by guillotine to collect blood. Other groups of
rats were given dc-ionized water (30 ml/kg) orally by a gastric
tube under transient, light ether anesthesia, allowed to awaken,
and then blood was taken by decapitation 60 mm later after the
oral water load. This time was chosen since our experiments
showed the maximal urine flow and the minimal urinary
osmolality (Uosm) occurred approximately 40 to 80 mm after
the oral water load. All blood samples were taken in heparin-
ized tubes on ice. These samples were centrifuged at 4°C and
3,000 rpm for 15 mm. The plasma was decanted into other tubes
and frozen at —20°C until the time of assay.
Plasma AVP was measured by radioimmunoassay using AVP
antiserum [15]. The samples were extracted by the Sep-pak
method. Sep-pak cartridges (Waters Associates, Milford, Mas-
sachusetts, USA) were initially washed twice with 5 ml of
methanol, and then rinsed with 12 ml of distilled water. 0.5 ml
of plasma with 0.5 ml of 0.1 N HC1 was applied into a Sep-pak
column, followed by washing with 10 ml of 4% acetic acid. The
samples were eluted with 1.5 ml of methanol and then dried
under a stream of nitrogen at room temperature. The precipi-
tations were dissolved in 0.8 ml of 0.1 M phosphate buffer (0.1
M phosphate buffer, 0.01% NaN3, 0.1% bovine serum albumin,
pH 7.4) and used to measure AVP by radioimmunoassay. The
lower limit of detection of the standard curves was 0.15 pg/mI.
A synthetic AVP (grade VI, designated activity of 367 lU/mg,
Sigma, St. Louis, Missouri, USA) was used for the standard
curves. Intra- and inter-assay coefficients of variation are less
than 10%. Lysine vasopressin show 100% immunoreactivity
when compared with AVP. l-Deamino-8-D-AVP show 1.3%
crossreactivity with the AVP antiserum. However, oxytocin,
arginine vasotocin and pressinoic acid crossreact by less than
0.1% with the AVP antiserum [15].
Other groups of IVC and sham—operated rats prepared in the
same manner were used to measure plasma osmolality (Posm).
1.2 ml of blood was taken from tail artery and vein under ether
anesthesia. Posm was measured by freezing—point depression
(Model 3R, Advanced Instruments, Inc., Needham Heights,
Massachusetts, USA).
Effect of the antidiuretic antagonist on renal water excretion
Acute oral water loads were carried out in IVC and
sham—operated rats to evaluate the effect of low cardiac output
on renal water excretion. The experiments were started two hrs
after removal of food and water in the following manner: the
rats were administered intraperitoneally 30 sg/kg of [l-(13-
mercapto-, /3-cyclopentamethylenepropionic acid), 2-(O-ethyl)
D-tyrosine, 4-valine] AVP, d(CH2)5D-Tyr(Et)VAVP [9], or the
vehicle, 2.5 x l0 M acetic acid and 0.9% saline, and 20 mm
later they were given 30 mI/kg of deionized water by a gastric
tube under light ether anesthesia. The animals were then placed
in individual metabolic cages (Natsume Inc., Tokyo, Japan) and
allowed to awaken. Spontaneously voided urine samples were
then collected at 20 mm intervals for three hrs [13]. The final
urine samples were obtained by abdominal massage at the end
of experiments. Urine volume and Uosm were measured and
percent of water load excreted and minimal Uosm were re-
corded. Uosm was measured by freezing—point depression.
Before the above experiment, the following study was per-
formed to determine what dose of d(CH2)5D-Tyr(Et)VAVP was
enough to block the antidiuretic action of endogenous AVP.
d(CH2)5D-Tyr(Et)VAVP was administered intraperitoneally
into normal hydrated Sprague—Dawley rats. Spontaneously
voided urine samples were collected at 30 mm intervals for
three hrs. The following data show the minimal Uosm
(mOsm/kg H20, mean saM) with the dose of the AVP
antagonist shown in bracket: 869.8 224.1 (vehicle); 423.6
Renal blood flow Kidney counts (cpm)
(mI/mmn/g) Femoral blood (cpm)
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33.0(5 gig/kgbody wt); 134.6 9.9 (15 p.glkg body wt); and 98.2
11,2 (30 g!kg body wt). Each group has five observations.
Effect of the vasopressor antagonist on mean arterial
pressure
Animals were used 48 hrs after the IVC operation. After
induction of anesthesia with ether, a catheter (PE-50,
Clay—Adams) was inserted into the left femoral vein for drug
administration. Another catheter was inserted into the left
femoral artery for monitoring blood pressure (Pressure trans-
ducer, Model PAS-lol, Star Medical Co., Tokyo, Japan; and
Model 056 Recorder, Hitachi Electric Co., Tokyo, Japan). The
rats then were placed in a restrainer and allowed to awaken. At
least two hrs after catheter insertion was allowed before the
experiments were started. The baseline mean arterial pressure
(MAP) was monitored until stable for at least 30 mm. Thereaf-
ter, the vasopressor antagonist, [1-(f3-mercapto-f3, /3-cyclo-
pentamethylenepropionic acid), 2-(Omethyl)-tyrosine] AVP,
d(CH2)5Tyr(Me)AVP (5 pg/kg body weight) or the vehicle
(0.9% saline containing 2.5 x l0 M acetic acid) was injected
intravenously in a volume of 0.4 ml [16, 17], and then MAP was
monitored for the next 60 mm. in all experiments the maximal
stable decrement in MAP was used for statistical analysis.
Effect of the antidiuretic antagonist on GFR
Experiments were also performed to ascertain whether the
antidiuretic antagonist, d(CH2)5D-Tyr(Et)VAVP affected gb-
merular filtration rate (GFR) in the IVC rats. After induction of
anesthesia with ether, catheters (PE-50) were inserted into the
external jugular vein and carotid artery. A suprapubic catheter
(PE-lOO) was inserted into the urinary bladder. The rats then
were placed in restraining cages and allowed to awaken. At
least two hrs passed after the animals had awakened before the
experiments were started. The animals were infused with 0.9%
saline containing 3H-methoxy-inulin (specific activity, 345
mCi/g, New England Nuclear, Boston, Massachusetts, USA) at
a rate of 7 mi/hr (7 Ci/hr) (Harvard pump) [181. After 60 mm,
three, 10 mm urine collections were made and then the
antidiuretic antagonist (30 pg/kg) was administered intraperito-
neally. Urine samples were then taken at 10 mm intervals for 60
mm. A blood sample was taken from the carotid artery line
before the administration of the antidiuretic antagonist and at
the end of the experiments. The concentrations of 3H-methoxy-
inulin were determined using Aloka LSC-671 Liquid Scintilla-
tion Spectrometer (Tokyo, Japan). Inulin clearance was calcu-
lated as an index of GFR [131.
Measurements of tissue solute contents
Solute contents of whole inner medulla (papilla) of the
kidneys were determined by the method of Appelboom et al
[19]. In these studies, the animals were killed after 48 hrs of the
IVC operation. The abdomen was opened and both kidneys
were removed rapidly and placed in an ice bath. The kidneys
were cut along their longitudinal axis and the inner medulla was
dissected free, weighed and freezed in liquid nitrogen. One
sample was for the determination of osmolality, sodium, potas-
sium and urea, while the other was dried to constant weight for
determination of tissue water content. Osmolality was mea-
sured by freezing—point depression. Sodium and potassium
contents were determined by flame photometry (Instrumenta-
tion Laboratories, Cidra, Puerto Rico), while urea was mea-
sured by urea nitrogen assay kit (Wako Junyaku Co., Tokyo,
Japan). The inner medullary tissue osmolality was finally cal-
culated from the observed osmolality. Also, this was confirmed
by calculating from sodium, potassium and urea contents [201.
Statistics
All values were compared between the groups by the
unpaired Student's t-test. Alterations in MAP within groups
were compared by the paired Student's t-test. A P value less
than 0.05 was considered significant.
Results
Systemic hemodynamic parameters in the IVC and the con-
trol, sham—operated rats are shown in Table 1. MAP was not
different between the groups, A cardiac index of 260.0 12.3
mI/mm/kg in the IVC rats was significantly less than that of
323.6 13.2 ml/min/kg in the sham—operated rats. In contrast,
peripheral vascular resistance was significantly greater in the
IVC rats than the sham—operated rats. Renal blood flow was
significantly lower in the IVC rats than the sham—operated rats.
However, there was no significant difference in renal vascular
resistance between the two groups. Heart weight was signifi-
cantly lighter in the IVC rats than the sham—operated rats.
Figure 1 shows Posm in the IVC rats and sham—operated rats
60 mm after an acute oral water load. Plasma osmolality was
decreased to 275.6 1.0 mOsm/kg H20 in the IVC rats, a value
significantly less than 280.1 1.3 mOsm/kg H20 of the
sham—operated rats. When the animals were allowed free
access to water and food, Posm was lower, but not significantly
different in the IVC rats as compared to the sham—operated rats
(283.3 3.3 vs. 287.6 2.2 mOsm/kg H20, N 8, NS).
Figure 2 shows plasma AVP levels during water intake ad
libitum (A) and 60 mm after an acute oral water load (B). When
the animals were allowed free access to water and food, plasma
AVP was significantly higher in the IVC rats than the
sham—operated rats. Sixty mm after an acute water load,
plasma AVP in the sham—operated rats was reduced to 0.7 0.2
pg/ml. In the IYC rats, however, the plasma AVP level of 2.1
0.6 pg/ml was not sufficiently suppressed by the administration
of water.
Figure 3 shows the effects of the antidiuretic antagonist vs.
the antagonist vehicle on minimal Uosm in the IVC and
sham—operated rats. In the sham—operated rats there was little
difference in minimal Uosrn between the vehicle and the
antidiuretic antagonist rats (97.9 10.6 vs. 82.1 3.7 mOsm/kg
H2O, NS). The minimal Uosm in the IVC rats receiving the
vehicle was markedly higher than that in the sham—operated
rats (P <0.01). The difference in the minimal Uosm in the IVC
rats between the vehicle and the antidiuretic antagonist was
quite evident (292.7 53.1 vs. 90.0 3.6 mOsm/kg H20, P <
0.01). This result demonstrates that endogenous AVP is an
important factor in the defect in urinary dilution in the IVC rats.
it is not evident that AYP-independent defect in urinary dilution
persists as minimal Uosm was not different between the IVC
and sham—operated rats in the presence of the antidiuretic
antagonist (90.0 3.6 vs. 82.1 3.7 mOsm/kg H20, NS). The
difference in the percent of water excreted in the IVC rats
between the vehicle and the antidiuretic antagonist was 51.4 ±
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Table 1. Systemic hemodynamic parameters in rats with inferior vena cava constriction and sham—operated rats.
Peripheral Renal
Mean vascular Renal vascular
arterial Cardiac resistance blood resistance Heart
pressure index mm Hg/mi! flow mm Hg/mi! weightN mm Hg mi/mm/kg mm/kg mi/minig minlg g/kg
IVC rats 8 102.6 3.2 260.0 12.3 0.397 0.019 4.9 0.4 21.67 1.76 3.48 0.13
Sham-operated 8 105.3 1.4 323.6 13.2 0.328 0.015 6.2 0.4 17.53 1.11 4.23 0.16
rats
P value NS <0.01 <0.05 <0.05 NS <0.01
Values are mean SEM.
300
290
0
E
0
E
270
280
260
250
Fig. 1. Plasma osmolality 60 mm after an acute oral water load in the
rats with inferior vena cava constriction and the sham—operated rats.
Values are mean SEM, P < 0.05.
5,9% vs. 143.7 9.4% (P < 0.01). Also, similar results were
obtained in the sham—operated rats (95.1 6.0% vs. 176.1
7.5%, P < 0.01). Effect of the antidiuretic antagonist vs. the
vehicle on renal solute excretion is shown by using UosmV.
UosmV were 12.3 1.0 and 11.0 1.0 iOsm/min in the IVC
rats receiving the vehicle and the antidiuretic antagonist, re-
spectively. Similarly, the sham-operated rats receiving the
vehicle and the antidiuretic antagonist had a UosmV of 10.8
0.8 and 11.7 0.8 tOsm/min, respectively. There was no
difference in solute excretion among any group.
Table 2 shows the effect of the antidiuretic antagonist on GFR
in IVC rats. The value of GFR in the JYC rats is slightly but not
significantly less when compared with the sham—operated rats.
Also, there was no significant difference in GFR between the
presence and absence of the antidiuretic antagonist. Inner
medullary solute contents were 1009.7 148.2 and 1196.7
86.0 mOsm/kg H20 in the IVC (N = 5) and the sham-operated
rats (N = 5) respectively, which was no statistically significant
between the two groups.
The MAP responses to either the vasopressor antagonist or
the vehicle are depicted in Figure 4. Baseline MAP was not
different among the four groups of the IVC and sham—operated
I
4
3
2
0
A
B
Fig. 2. Plasma AVP levels during water intake ad libitum (A) and 60
,nin after an acute oral water load (B) in the rats with inferior vena cava
constriction and the sham-operated rats. Values are mean SCM, P <
0.05.
rats. There were no alterations in MAP in response to either the
vasopressor antagonist or the vehicle in either IVC or
sham-operated animals.
Sham—operated
(9)
Ivc
3
0
Sham—operated (VC
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Sham—operated IVC
Fig. 3. Effects of the antidiuretic antagonist (C) vs. the antagonist
vehicle (n) on minimal Uosm in the rats with inferior vena cava
constriction and the sham—operated rats. Values are mean 5EM.
Discussion
Acute constriction of the thoracic inferior vena cava in dogs
decreases cardiac output and increases total peripheral vascular
resistance [3, 211. Anderson and his associates demonstrated
that in this dog model, low cardiac output causes impaired
water excretion which is associated with the elevated levels of
plasma AVP [31. The maneuver which causes constriction of
the subdiaphragmatic portion of the inferior vena cava proximal
to the hepatic vein can reproduce this experimental model of
low cardiac output. The cardiac output was significantly lower
in the experimental group than the control, sham—operated rats.
In contrast to acute constriction of the thoracic inferior vena
cava in dogs which decreases MAP, the MAP remained un-
changed in the IVC rats 48 hrs after the constriction. The
present model of rats is therefore useful to evaluate the patho-
genesis of impaired water excretion associated with low cardiac
output.
Congestive heart failure has been known to be associated
with impaired water excretion in both man and animals [1—51. In
recent years the suggested mechanisms for this impaired water
excretion have included persistent release of AVP in the
presence of hypoosmolality [3—51 and intrarenal factors [6, 71.
The present results provide strong confirmatory evidence for a
role of plasma AVP in the impaired water excretion associated
with this model of low cardiac output. The radioimmunoassay-
GFR (mI/mm)
P valueBasal AVP Antagonist
IVC rats, N = 6
Sham—operated ratsN=6
P value (IVC vs. Sham)
2.5 0.2
2.8 0.2
NS
2.4 0.2
2.9 0.3
NS
NS
NS
Fig. 4. Effect of the inferior vena cava constriction on mean arterial
pressure (MAP) response to the vasopressor antagonist in the con-
scious rats. Symbols are: •, group with vehicle; 0, group with the
vasopressor antagonist, d(CHJ5Tyr(Me)AVP (5 jig/kg body wt, i.v.).
Values are mean 5EM. Each group has ten observations.
able plasma levels of AVP was increased significantly in the
1VC rats, despite a relatively lower Posm than the sham—oper-
ated rats. Also, nonsuppressible radioimmunoassayable levels
of plasma AVP were demonstrable in the presence of hypoos-
molality in the IVC rats during an acute oral water load, that
suppresses plasma AVP in normal animals to less than I pg/mt.
Thus, the elevation of plasma AVP should be related to
non-osmotic stimulus, that is, the diminution in cardiac output,
as suggested by the previous studies [3, 22, 23]. It has hereto-
fore been believed possible that the elevated plasma AVP was
not exerting a physiological effect on renal water excretion. The
administration of the antidiuretic antagonist, d(CH2YsD-
Tyr(Et)VAVP, resulted in a marked improvement in water
excretion in the IVC rats. In the presence of the antidiuretic
antagonist, the minimal Uosm in the IVC rats was at a compa-
rable level to that in the control rats and the percent of water
excreted exceeded over 100%. The latter was due probably to
the sustained effect of the antidiuretic antagonist during the
acute water load, because in its absence maximal urine flow rate
occurs between 40 and 80 mm, followed by a gradual decrease.
Similar results were obtained in the control rats; the minimal
Uosm was not different in the presence or absence of the
antidiuretic antagonist, but the percent of water excreted in-
creased markedly in its presence.
A series of the antidiuretic antagonists, developed by Man-
ning, Sawyer and their associates [8—12], exert potent inhibitory
effects on the antidiuretic action of AVP. d(CH2)5D-Tyr
(Et)VAVP used in this study has a pA2 value of 7.81 [9], which
PT
P C 0.01
1
Table 2. Effect of the antidiuretic antagonist d(CH2)5D-Tyr(Et)VAVP
on glomerular filtration rate (GFR) in rats with inferior vena cava
constriction.
300
0
I
200
100
Sham—operated Rats JVC rats
NS
-3
t—
E
E
a-C
100
50
0
-I-
(10)
NS
100
50
0
(10)
Before After Before After
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improvement of the pathological state of water retention in
some forms of congestive heart failure.
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